Company Oxygen Biotherapeutics Inc Nasdaq

Equities

US69207P3082

Biotechnology & Medical Research

Business Summary

Managers

Members of the board

Share class

Shareholders

Company contact information

Sector

Sector Other Biotechnology & Medical Research

Inactive Instrument

End-of-day quote Nasdaq Other stock markets
- ^USD	-

Mar. 28	Tenax Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	CI
Mar. 28	Tenax Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	CI

Tenax Therapeutics, Inc. is a Phase 3 development-stage pharmaceutical company. The Company is focused on identifying, developing, and commercializing products that address cardiovascular and pulmonary diseases with high unmet medical needs. The Company's products include TNX-201 (oral enteric coated imatinib) and TNX-103 (oral levosimendan). The Company is developing dosing and a formulation of imatinib mesylate, a kinase inhibitor for the treatment of pulmonary arterial hypertension (PAH). The Companyâs other programs include TNX-101 (IV), TNX-102 (subcutaneous) and TNX-103 (oral) levosimendan. Levosimendan is a calcium sensitizer/K-ATP activator developed for intravenous use in hospitalized patients with acutely decompensated heart failure. The Company has completed the Phase II trial of levosimendan in patients with PH and heart failure with preserved ejection fraction (HFpEF).

Managers	Title	Age	Since
Christopher T. Giordano CEO	Chief Executive Officer	50	21-07-13
Lawrence R. Hoffman DFI	Director of Finance/CFO	69	Jan. 10
Stuart Rich CTO	Chief Tech/Sci/R&D Officer	74	21-01-14
Doug Randall COO	Chief Operating Officer	-	13-11-13
Douglas Hay LAW	General Counsel	-	13-11-13

Members of the board	Title	Age	Since
Gerry Proehl CHM	Chairman	65	14-04-03
June Almenoff BRD	Director/Board Member	67	21-02-24
Declan Doogan BRD	Director/Board Member	72	21-02-24
Michael Davidson BRD	Director/Board Member	67	21-02-24
Robyn Hunter BRD	Director/Board Member	62	22-01-27
Stuart Rich CTO	Chief Tech/Sci/R&D Officer	74	21-01-14
Christopher T. Giordano CEO	Chief Executive Officer	50	21-07-13

	Vote	Quantity	Free-Float	Company-owned shares	Total Float
Stock A	0	210	0	0	99.65 %
Stock B	1	1,958,245	1,951,298 ( 99.65 %)	0

Name	Equities	%	Valuation
Heights Capital Management, Inc. 11.55 %	204,027	11.55 %	865 074 $
S.H.N. Financial Investments Ltd. 6.059 %	107,000	6.059 %	453 680 $
The Lind Partners LLC 4.049 %	71,500	4.049 %	303 160 $
Armistice Capital LLC 0.9763 %	17,241	0.9763 %	73 102 $
Renaissance Technologies LLC 0.2408 %	4,252	0.2408 %	18 028 $
Stuart Rich 0.1502 %	2,652	0.1502 %	11 244 $
Corient Private Wealth LLC 0.1352 %	2,387	0.1352 %	10 121 $
Vanguard Group, Inc. (Subfiler) 0.1317 %	2,326	0.1317 %	9 862 $
Declan Doogan 0.1288 %	2,274	0.1288 %	9 642 $
Geode Capital Management LLC 0.1048 %	1,851	0.1048 %	7 848 $

Tenax Therapeutics, Inc.

101 Glen Lennox Drive Suite 300

27517, Chapel Hill

+919 855 2100

http://www.tenaxthera.com

Healthcare

Pharmaceuticals & Medical Research

Biotechnology & Medical Research

Biotechnology & Medical Research

Other Biotechnology & Medical Research

	1st Jan change	Capi.
IQVIA HOLDINGS INC.	-1.82%	41.36B
LONZA GROUP AG	+44.25%	41.3B
MODERNA, INC.	+2.56%	39.61B
CELLTRION, INC.	-12.11%	25.62B
ICON PUBLIC LIMITED COMPANY	+3.09%	24.09B
ALNYLAM PHARMACEUTICALS, INC.	-24.16%	18.38B
MEDPACE HOLDINGS, INC.	+22.12%	11.85B
CHARLES RIVER LABORATORIES INTERNATIONAL, INC.	-3.74%	11.82B
UNITED THERAPEUTICS CORPORATION	+7.75%	11.07B

Other Biotechnology & Medical Research